Leishmaniasis: Current aspects on epidemiology, clinical syndromes, diagnosis, prevention, and treatment

被引:0
作者
Tzanetou, K. [1 ]
机构
[1] G Gennimatas Gen Hosp Athens, Dept Microbiol, Athens, Greece
来源
ARCHIVES OF HELLENIC MEDICINE | 2005年 / 22卷 / 03期
关键词
Clinical syndromes; Leishmaniasis; Leishmania spp; Treatment;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leishmaniasis is characterized by a variety of clinical syndromes, the most severe being that of visceral leishmaniasis. During recent years an increase of disease incidence has been noted in most endemic areas, including Greece. The purpose of this review is to report the progress in diagnosis, treatment, prevention, and control of the infection. The three major clinical syndromes (visceral, cutaneous and mucocutaneous) are discussed along with details of the causative Leishmania species, the epidemiological features, the conventional and the newer diagnostic methods, the parasite identification techniques at species and subspecies levels, the new therapeutic options and vector and reservoir control measures. Suspicion of the disease, accurate diagnosis and prompt treatment decrease the mortality from visceral leishmaniasis and contribute to the interruption of the transmission cycle and success of infection control in the countries where the parasitic disease is endemic.
引用
收藏
页码:239 / 253
页数:15
相关论文
共 40 条
[1]   A CASE OF MUCOCUTANEOUS LEISHMANIASIS IN SAUDI-ARABIA CAUSED BY LEISHMANIA-MAJOR AND ITS RESPONSE TO TREATMENT [J].
ALGINDAN, Y ;
OMER, AHS ;
AHUMAIDAN, Y ;
PETERS, W ;
EVANS, DA .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1983, 8 (02) :185-+
[2]  
[Anonymous], COMM DIS SURV RESP
[3]   Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis [J].
Attar, ZJ ;
Chance, ML ;
el-Safi, S ;
Carney, J ;
Azazy, A ;
El-Hadi, M ;
Dourado, C ;
Hommel, M .
ACTA TROPICA, 2001, 78 (01) :11-16
[4]   Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) :684-703
[5]   US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis - Editorial response [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) :49-51
[6]   Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis [J].
Bossolasco, S ;
Gaiera, G ;
Olchini, D ;
Gulletta, M ;
Martello, L ;
Bestetti, A ;
Bossi, L ;
Germagnoli, L ;
Lazzarin, A ;
Uberti-Foppa, C ;
Cinque, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (11) :5080-5084
[7]  
CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475
[8]  
Das V N, 2001, J Assoc Physicians India, V49, P609
[9]   Leishmaniasis: new approaches to disease control [J].
Davies, CR ;
Kaye, P ;
Croft, SL ;
Sundar, S .
BRITISH MEDICAL JOURNAL, 2003, 326 (7385) :377-382
[10]   Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy [J].
de la Rosa, R ;
Pineda, JA ;
Delgado, J ;
Macías, J ;
Morillas, F ;
Mira, JA ;
Sánchez-Quijano, A ;
Leal, M ;
Lissen, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (03) :762-767